Elevance Health Surges to 167th in Trading Volume with $679 Million Turnover

On March 31, 2025, Elevance Health (ELV) saw a significant increase in trading volume, with a turnover of $679 million, marking a 38.01% rise from the previous day. This surge placed Elevance Health at the 167th position in terms of trading volume for the day. The stock price of Elevance Health has been on an upward trajectory, rising by 0.69% and marking its fourth consecutive day of gains, with a total increase of 2.71% over the past four days.

Over the past year, several insiders at Elevance Health have sold substantial stakes in the company, which has raised eyebrows among investors. While insider selling can have various explanations, it is noteworthy when multiple insiders sell shares over a specific period. The largest single sale occurred when Felicia Norwood, the Executive VP & President of Government Health Benefits, sold $6.8 million worth of shares at $535 per share. Although insider selling is generally not a positive sign, this sale was made at a price significantly higher than the current stock price of $432, making it less concerning.

In the last quarter, there was notable insider selling, with insiders disposing of $1.6 million worth of shares. This lack of buying activity has raised some caution among investors. However, it is important to note that insiders at Elevance Health own approximately $115 million worth of shares, which is 0.1% of the company. This level of insider ownership suggests that management incentives are aligned with those of other shareholders, which is generally seen as a positive sign.

Despite the recent insider selling, Elevance Health remains a profitable and growing company. While the lack of insider buying and the recent sales may cause some concern, the overall alignment of management interests with shareholders is a reassuring factor. Investors should consider these points along with other risks and opportunities when evaluating Elevance Health as an investment.